MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jjco/hyag107

Медицинская библиотека · Japanese journal of clinical oncology · 2026

Screening for prognostic indicators in patients with metastatic castration-resistant prostate cancer after androgen receptor signaling inhibitor treatment for metastatic castration-sensitive prostate cancer.

Hayakawa Keita, Ueda Takashi, Gabata Yusuke, Murashita Junki, Takahashi Hikaru, Saito Yumiko, Miyashita Masatsugu, Shiraishi Takumi, Fujihara Atsuko, Okumi Masayoshi, Hongo Fumiya, Ukimura Osamu

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Androgen receptor signaling inhibitors (ARSI) and docetaxel (DTX) are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, the differences in therapeutic efficacy between these treatments for mCRPC after upfront ARSI for metastatic castration-sensitive prostate cancer (mCSPC) remain unclear. In this study, we used real-world data to compare treatment efficacy and to identify prognostic indicators.

METHODS

We retrospectively analyzed 120 patients who progressed to mCRPC after receiving ARSI as a first-line therapy for mCSPC. Second-line progression-free survival (PFS) and second-line overall survival (OS) were compared between the DTX and non-DTX groups. Cox proportional hazards regression analysis was performed to identify the prognostic indicators of second-line OS in patients with mCRPC. Propensity score matching was used to adjust for differences in baseline clinical characteristics.

RESULTS

Among matched patients with mCRPC, no significant differences were observed in second-line PFS or OS between the non-DTX and DTX groups. Univariate and multivariate analyses demonstrated that pretreatment serum lactate dehydrogenase (LDH) levels (<220 vs. ≥220 U/l) and Gleason pattern 5 (GP5) status were significant prognostic indicators for second-line OS in patients with mCRPC.

CONCLUSIONS

Pretreatment LDH levels and GP5 status may be useful prognostic indicators for patients with mCRPC following upfront ARSI therapy for mCSPC.

Для цитирования: Hayakawa Keita, Ueda Takashi, Gabata Yusuke, Murashita Junki, Takahashi Hikaru, Saito Yumiko, Miyashita Masatsugu, Shiraishi Takumi, Fujihara Atsuko, Okumi Masayoshi, Hongo Fumiya, Ukimura Osamu. Screening for prognostic indicators in patients with metastatic castration-resistant prostate cancer after androgen receptor signaling inhibitor treatment for metastatic castration-sensitive prostate cancer.. Japanese journal of clinical oncology. 2026. DOI: 10.1093/jjco/hyag107.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.